Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The immune system’s first encounter with a virus or vaccine establishes a “starting template” that shapes its response to new ...

Thanks to the Human Genome Project, researchers have sequenced all 3.2 billion base pairs in the human genome. How did researchers complete this chromosome map years ahead of schedule? Initial ...

With a single click, unlock detailed, AI-assisted insights pulled from hundreds of financial data points instantly.